Literature DB >> 19995923

Epitope switching as a novel escape mechanism of HIV to CCR5 monoclonal antibodies.

Andreas Jekle1, Milloni Chhabra, Adriane Lochner, Sonja Meier, Eugene Chow, Michael Brandt, Surya Sankuratri, Nick Cammack, Gabrielle Heilek.   

Abstract

In passaging experiments, we isolated HIV strains resistant to MAb3952, a chemokine (C-C motif) receptor 5 (CCR5) monoclonal antibody (MAb) that binds to the second extracellular domain (extracellular loop 2 [ECL-2]) of CCR5. MAb3952-resistant viruses remain CCR5-tropic and are cross-resistant to a second ECL-2-specific antibody. Surprisingly, MAb3952-resistant viruses were more susceptible to RoAb13, a CCR5 antibody binding to the N terminus of CCR5. Using CCR5 receptor mutants, we show that MAb3952-resistant virus strains preferentially use the N terminus of CCR5, while the wild-type viruses preferentially use ECL-2. We propose this switch in the CCR5 binding site as a novel mechanism of HIV resistance.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19995923      PMCID: PMC2812136          DOI: 10.1128/AAC.00841-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  28 in total

1.  Mapping the determinants of the CCR5 amino-terminal sulfopeptide interaction with soluble human immunodeficiency virus type 1 gp120-CD4 complexes.

Authors:  E G Cormier; D N Tran; L Yukhayeva; W C Olson; T Dragic
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

2.  Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4.

Authors:  Chih-Chin Huang; Son N Lam; Priyamvada Acharya; Min Tang; Shi-Hua Xiang; Syed Shahzad-Ul Hussan; Robyn L Stanfield; James Robinson; Joseph Sodroski; Ian A Wilson; Richard Wyatt; Carole A Bewley; Peter D Kwong
Journal:  Science       Date:  2007-09-28       Impact factor: 47.728

3.  CD4-BFFI: a novel, bifunctional HIV-1 entry inhibitor with high and broad antiviral potency.

Authors:  Andreas Jekle; Eugene Chow; Erhard Kopetzki; Changhua Ji; Mei Jun Yan; Rosa Nguyen; Surya Sankuratri; Nick Cammack; Gabrielle Heilek
Journal:  Antiviral Res       Date:  2009-06-25       Impact factor: 5.970

4.  Adaptation to blockade of human immunodeficiency virus type 1 entry imposed by the anti-CCR5 monoclonal antibody 2D7.

Authors:  E J Aarons; S Beddows; T Willingham; L Wu; R A Koup
Journal:  Virology       Date:  2001-09-01       Impact factor: 3.616

5.  Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection.

Authors:  Raphael J Landovitz; Jonathan B Angel; Christian Hoffmann; Heinz Horst; Milos Opravil; Jianmin Long; Wayne Greaves; Gerd Fätkenheuer
Journal:  J Infect Dis       Date:  2008-10-15       Impact factor: 5.226

6.  CD4-anchoring HIV-1 fusion inhibitor with enhanced potency and in vivo stability.

Authors:  Changhua Ji; Erhard Kopetzki; Andreas Jekle; Kay-Gunnar Stubenrauch; Xingrong Liu; Jun Zhang; Eileen Rao; Tilman Schlothauer; Stephan Fischer; Nick Cammack; Gabrielle Heilek; Stefan Ries; Surya Sankuratri
Journal:  J Biol Chem       Date:  2008-12-19       Impact factor: 5.157

Review 7.  Maraviroc, a chemokine CCR5 receptor antagonist for the treatment of HIV infection and AIDS.

Authors:  Nicholas A Meanwell; John F Kadow
Journal:  Curr Opin Investig Drugs       Date:  2007-08

8.  Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults.

Authors:  Jeffrey M Jacobson; Michael S Saag; Melanie A Thompson; Margaret A Fischl; Ralph Liporace; Richard C Reichman; Robert R Redfield; Carl J Fichtenbaum; Barry S Zingman; Mahesh C Patel; Jose D Murga; Suzanne M Pemrick; Paul D'Ambrosio; Marti Michael; Hans Kroger; Hieu Ly; Yakov Rotshteyn; Robert Buice; Stephen A Morris; Joseph J Stavola; Paul J Maddon; Alton B Kremer; William C Olson
Journal:  J Infect Dis       Date:  2008-11-01       Impact factor: 5.226

9.  Characterization of a human immunodeficiency virus type 1 V3 deletion mutation that confers resistance to CCR5 inhibitors and the ability to use aplaviroc-bound receptor.

Authors:  Katrina M Nolan; Gregory Q Del Prete; Andrea P O Jordan; Beth Haggarty; Josephine Romano; George J Leslie; James A Hoxie
Journal:  J Virol       Date:  2009-02-04       Impact factor: 5.103

10.  Closing two doors of viral entry: intramolecular combination of a coreceptor- and fusion inhibitor of HIV-1.

Authors:  Erhard Kopetzki; Andreas Jekle; Changhua Ji; Eileen Rao; Jun Zhang; Stephan Fischer; Nick Cammack; Surya Sankuratri; Gabrielle Heilek
Journal:  Virol J       Date:  2008-05-01       Impact factor: 4.099

View more
  2 in total

1.  Development of tetravalent, bispecific CCR5 antibodies with antiviral activity against CCR5 monoclonal antibody-resistant HIV-1 strains.

Authors:  Jürgen Schanzer; Andreas Jekle; Junichi Nezu; Adriane Lochner; Rebecca Croasdale; Marianna Dioszegi; Jun Zhang; Eike Hoffmann; Wilma Dormeyer; Jan Stracke; Wolfgang Schäfer; Changhua Ji; Gabrielle Heilek; Nick Cammack; Michael Brandt; Pablo Umana; Ulrich Brinkmann
Journal:  Antimicrob Agents Chemother       Date:  2011-02-07       Impact factor: 5.191

2.  Susceptibility of HIV type 2 primary isolates to CCR5 and CXCR4 monoclonal antibodies, ligands, and small molecule inhibitors.

Authors:  Maria Espirito-Santo; Quirina Santos-Costa; Marta Calado; Patrick Dorr; J Miguel Azevedo-Pereira
Journal:  AIDS Res Hum Retroviruses       Date:  2011-10-03       Impact factor: 2.205

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.